AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay
On 9 March, at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, during a symposium on amyloid beta…
On 9 March, at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, during a symposium on amyloid beta…
On 8 March, at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, during a symposium titled “Therapeutic Intervention…
On 7 March, at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, during a symposium sponsored by TauRx,…
At the AD/PD 2024 International Conference on Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), innovative approaches poised to revolutionise the…
On 5 March 2024, Innovent Biologics and Anheart Therapeutics announced the Chinese National Medical Products Administration (NMPA)’s acceptance of the…
In late 2023, the Medicines and Healthcare products Regulatory Agency approved Vertex’s Casgevy, which became the inaugural clustered regularly interspaced…
GlobalData’s recent survey The State of the Biopharmaceutical Industry 2024 revealed that 44% of healthcare industry professionals surveyed globally are…
The top 20 biopharmaceutical companies saw prominent shifts in market capitalisation over 2023 despite macroeconomic challenges, upcoming patent cliffs, and…
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a swiftly advancing, fatal neurodegenerative condition marked by muscle…
On 31 January 2024, Biogen announced that it will discontinue the development and commercialisation of Aduhelm (aducanumab), its anti-amyloid beta…